Page 1

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tab - Cel® Pierre Fabre to Commercialize Tab - cel® for EBV + Cancers in ATARA BIO Europe , Middle East , Africa , and Other Select Emerging Markets • Pierre Fabre brings significant oncology commercialization capabilities in the territory • Tab - cel® will benefit from Pierre Fabre Oncology Business Unit while leveraging its network in Bone Marrow Transplant and track record of partnerships • Atara will retain full commercialization rights to Tab- cel® in other major markets , including North America , Asia Pacific and Latin America • Collaboration maximizes the current opportunity for Tab - celⓇ outside the U.S. , while avoiding commercial infrastructure build and complexity for Atara in Europe ATARA BIO Pierre Fabre • Atara to receive upfront payment of $ 45 million , and up to ~ $ 320 million in milestones , plus significant double - digit tiered royalties as a percentage of net sales • Atara will continue to be responsible for the pivotal ALLELE study in PTLD as well as submitting the Europe Marketing Authorization Application ( MAA ) • Pierre Fabre will lead all commercialization and distribution activities in its territory , as well as medical and regulatory activities after the anticipated MAA approval in Europe Tab - celⓇ , recently granted EMA accelerated assessment , remains on - track for EU MAA filing in Nov 2021 1